Commentary: tumor growth, patient survival, and the search for the optimal phase II efficacy endpoint.
Takimoto
Chris H
CH
Ortho Biotech Oncology R&D/Centocor R&D, Radnor, Pennsylvania 19087, USA. ctakimot@its.jnj.com
D048708:Cell Growth Processes / Q000502:physiology; D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D023381:Endpoint Determination; D006801:Humans; D008297:Male; D008954:Models, Biological; D011471:Prostatic Neoplasms / Q000473:pathology; D016019:Survival Analysis